絞り込み

16636

広告

Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.

著者 Bruins Slot KM , Berge E
Cochrane Database Syst Rev.2013 Aug 8 ; 8():CD008980.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Department of Internal Medicine, Oslo University Hospital, Oslo, Norway, NO-0407.

スターを付ける スターを付ける     (583view , 0users)

Full Text Sources

Medical

Miscellaneous

Other Literature Sources

Anticoagulant treatment with vitamin K antagonists (VKAs) is aimed at preventing thromboembolic complications and has been the therapy of choice for most people with non-valvular atrial fibrillation (AF) for many decades. A new class of anticoagulants, the factor Xa inhibitors, appear to have several pharmacological and practical advantages over VKAs.
PMID: 23925867 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード